Dear Editor: Many antidepressants, either alone or in combination, can induce mania. Mirtazapine is a new noradrenergic and specific serotinergic antidepressant that has been associated with mania when used to augment fluoxetine (1) and with hypomania when combined with sertraline (2). Bhanji and others have recently proposed a "norepinephrine syndrome" of dysphoric mania that is based on mirtazapine's mechanism of action and a constellation of symptoms it likely caused when prescribed at high dosages (3) . We report the case of a young woman who went on a shopping spree after mirtazapine was added to paroxetine that was unsuccessful in treating her depression.
Case Report
The patient is a mother of 3, aged 35 years, with a positive family history of unipolar depression. Seven years earlier, she had been diagnosed with postpartum depression that was successfully treated with paroxetine. After stopping the paroxetine, she remained well until recently, when she presented to her family physician with complaints of fatigue, decreased libido, loss of interest, bouts of tearfulness, and panic attacks. Her doctor started her on paroxetine 10 mg daily and subsequently referred her to the local psychiatrist, who confirmed the diagnosis of a major depressive illness and increased her paroxetine gradually to 50 mg daily. Despite the above regimen, she continued to suffer from depression, except for rare good days when she was able to do some of her housework. To relieve the depression, bupropion, olanzapine, and L-tryptophan were separately added to the paroxetine, but with little success. After stopping the above 3 agents because they failed to boost the antidepressant effect of paroxetine, her psychiatrist added mirtazapine to her treatment. The dosage was gradually increased to 45 mg daily, and she took the combination for 8 weeks. Around this time, the patient was referred to the Mood Disorder Service for consultation. She reported that she had become irritable and impulsive. She described herself as easily "snapping" at people. Her energy had increased and she had started binge eating for the first time. Most dramatically, she began to make large purchases; for example, she bought 10 T-shirts and 5 pairs of shorts for her children, 5 pairs of pants and 8 pairs of shorts for herself, and magnifying glasses for many of the neighbourhood children. Her husband had to return all these items.
Mirtazapine-induced hypomania was recognized, the mirtazapine was discontinued, and the shopping sprees ceased soon thereafter. The remaining hypomanic symptoms also subsided later. However, the patient experienced depression. Her mood has stabilized with the addition of lithium carbonate.
Conclusion
The sudden episode of excessive and inappropriate spending resolved promptly when the offending agent, mirtazapine, was discontinued. We believe this is the first case of a shopping spree that was precipitated by the addition of mirtazapine to paroxetine when the latter failed to treat depressive symptoms.
Eric Prost, MD, Gaby Abraham, MD, FRCPC Kingston, Ontario

Age at Onset of Bipolar II Disorder
Dear Editor: Recently, 3 subgroups of bipolar I disorder (BD I), distinguished by different ages at onset, were found (1). Bipolar II disorder (BD II) has been found (according to Kolmogorov-Smirnov test) to have an age-at-onset distribution similar to that of BD I (2). Nevertheless, family studies (an important diagnostic validator) also support a distinction between the 2 disorders (3). The aim of the study reported here was to test whether BD II has 3 age-at-onset subgroups, as reported for BD I.
The study setting, patients, and interview methods are reported in detail elsewhere (4). The study setting was a private practice that has for many years studied BD II (see Benazzi F on PubMed/Medline). The study sample comprised 320 consecutively presenting outpatients (mean age of 41.6 years, SD 13.4) with BD II, 50.2% of whom had a family history of BD, and 68.4% of whom were women. Age at onset of the first major depressive episode (MDE) was assessed with the Structured Clinical Interview for DSM-IV-Clinician Version (5) , often supplemented by interviews of family members or close friends.
With regard to onset-age of the first MDE, the mean (SD) age was 22.8 years (10.6), the median age was 20 years, and the age range was 4 to 67 years. Histogram and kernel density estimates were employed to study distribution of age at onset. A histogram results in disproportional representation of density at the centre and in the tails of the distribution, whereas kernel estimators are nonparametric histogram smoothers revealing multimodality. A histogram provides accurate pictures of categorical variables; univariate kernel density estimate is better to represent continuous variables (STATA 7 statistical software; 6). For this sample of patients with BD II, both histogram and kernel density estimate showed 3 age-at-onset subgroups: around age 19 years, around age 27 years, and around age 35 to 40 years (figures available on request from the author). Onset before age 20 years was present in 45.0% (144/320), onset between age 19 and 35 years in 42.8% (137/320), and onset after age 35 years in 12.2% (39/320).
Discussion
The similar results achieved from 2 different statistical approaches compared with the Bellivier and others study support the validity of these findings. Age-at-onset distribution in BD II was found to be similar to that in BD I, as reported by Bellivier and others (1). Because onset is an important diagnostic validator (2, 7, 8) , finding 3 similar age-at-onset subgroups in BD I and BD II supports the hypothesis of a closer link between BD I and BD II. When more advanced statistical methods are used, the findings do not replicate the bimodality of onset that Kraepelin describes for manic-depressive insanity (8) .
Franco Benazzi, MD, Forli, Italy
Venlafaxine-Associated Hypomania in Unipolar Depression
Dear Editor: Antidepressant-induced hypomania and mania have been reported more commonly in cases of bipolar depression than in cases of unipolar depression (1). Tricyclic antidepressants, monoamine oxidase inhibitors, and even selective serotonin reuptake inhibitors have been associated with this switch (1) . Newer antidepressants like venlafaxine, which act on multiple specific receptors, have low propensity for the switch (2) but are not completely safe, particularly in patients with bipolar depression or with family history of bipolarity (3) (4) (5) . The following case report illustrates that venlafaxine may also be associated with a switch to hypomania in unipolar depression.
Case Report
Mr S, aged 26 years and single, presented to our clinic with a 2-year history of sustained sadness of mood, withdrawal, decreased interest in enjoyable activities, increased tiredness, ideas of hopelessness and worthlessness, past attempted suicide, death wish, and decreased sleep and appetite. One year earlier, he had undergone treatment including electroconvulsive therapy (twice) from a private psychiatrist but did not perceive significant benefit. He had been off medication for the 6 months prior to presentation. Two years earlier, his elder brother had committed suicide at age 30 years, following an altercation with family members. Apart from this, there was no personal or family history of affective illness, panic disorder, obsessive-compulsive disorder, substance use, or psychosis. No delusions or hallucinations were forthcoming, either at the time of assessment or historically. Results of a general physical examination and laboratory investigation, including a thyroid function test, were normal. He was diagnosed with severe depression without psychotic symptoms, and treatment with venlafaxine 75 mg daily, together with clonazepam 0.5 mg daily to promote sleep, was started. In the next 3 weeks, he reported 50% improvement in overall symptoms. At the end of week 3, venlafaxine was increased to 112.5 mg daily to enhance his improvement.
At the end of 5 weeks of total treatment, he was noticed to have decreased sleep, overactivity, overtalkativeness, and excessive cheerfulness. He was cracking jokes, voicing grandiose ideas, spending excessively, and smoking more. During interview, he subjectively complained of racing thoughts and new ideas. He himself had discontinued his increased medication after 2 weeks because he felt well. His symptoms continued until his family members brought him to hospital. Drug-induced hypomanic switch was considered, and lithium carbonate was started, along with benzodiazepine. At the end of 4 weeks, he became asymptomatic.
The patient developed possible venlafaxineinduced switch within 8 weeks of starting the medication (6) , and the symptoms continued, although they did not worsen, even after he stopped taking the drug. The presence of predisposing factors for bipolarity (7) , that is, early age of onset, long duration of a depressive episode, and a family history of suicide, probably made this patient vulnerable to a switch to hypomania on taking therapeutic dosages of venlafaxine, as shown by similar cases in the literature (3) . It is important to acknowledge that it is difficult to prove a causal connection between the introduction of venlafaxine and onset of hypomania, but venlafaxine possibly exposed latent bipolarity in this patient, which led to rapid institution of a mood stabilizer to prevent further morbidity.
Prior to starting any antidepressant, clinicians should attempt to obtain risk factors for bipolarity (that is, cyclothymic or hyperthymic temperament, early onset of depression, acute onset, atypical symptoms, seasonal pattern, and family history of bipolar disorder) to help in early detection and intervention when a manic or hypomanic switch occurs.
Prabhat K Chand, MD, DNB Ganjigunte S Kalyani, MBBS Pratima Murthy, MD Bangalore, India
Hypnopompic Hallucinations During Olanzapine Treatment
Deear Editor: A young man, aged 22 years, was taken for a psychiatric consultation after he had expressed death threats toward his cousin. From the information supplied, it was deduced that he had dramatically reduced his social contacts over the past 3 years and had given up all the activities that he previously enjoyed. After the consultation, we were able to draw a clinical picture that was characterized by indifference, bizarre behaviour, serious relational difficulties, and withdrawal from activities and interests. Judging from the current symptomology and from the clinical history, we diagnosed schizophrenia. As the main symptoms were negative, we decided to prescribe olanzapine. The starting dosage was 5 mg daily, gradually increased to 20 mg daily over a 1-month period. Our patient had never taken any psychotropic drug. Apart from the disappearance of paranoid symptoms (which had manifested themselves as death threats toward his cousin) a few days after the patient reached the olanzapine dosage of 20 mg daily, we also noticed improvement in the bizarre behaviour that had affected some of his daily activities. His social contacts also improved significantly. However, the therapy made the patient complain of a persistent sedative state and, strangely enough, he reported that upon waking he saw large spiders walking across the ceiling. Having noticed great therapeutic results despite the patient's complaints of sedative effects, and because he did not
